The prominent cardiovascular
research conducted at the Heart
Center at Newark Beth Israel Medical
Center helps patients gain access to
promising new treatments and
technologies. Our researchers
participate in industry sponsored and
investigator initiated clinical trials
that encompass general and
interventional cardiology,
electrophysiology, heart failure, heart
transplant, cardiac surgery and
ventricular assist devices. The entire
team works closely to incorporate
research findings into the
comprehensive care to improve
patient outcomes.
Newark Beth Israel remains one of the
leading enrolling centers for the
nationwide HeartMate II LVAS trial
that is evaluating the device as a
bridge to transplant and as destination
therapy. The results of the TIC-TAC
trial initiated by David Baran, MD,
Director of Heart Failure and
Transplant Research, is making news
world-wide regarding
immunosuppressive therapy in heart
transplant recipients.
Clinical evaluation of
cardiac support device: a feasibility trial
protocol; Principal Investigator: Margarita
Camacho, MD
Clinical evaluation of
Acorn Cardiac Support Device Therapy
in patients with dilated cardiomyopathy—
A confirmatory trial; Principal
Investigator: Margarita Camacho, MD
Double-blind, placebocontrolled,
multi-center acute study of
clinical effectiveness of Nesiritide in
subjects with decompensated heart failure;
Principal Investigator: David Baran, MD
Acute STEMI treated
with primary angioplasty and intravenous
enoxaparin or unfractionated heparin to
lower ischemia and bleeding events at
short and long-term follow-up; Principal
Investigator: Marc Cohen, MD
Multi-center, randomized,
controlled study of mechanical left
ventricular unloading with
counterpulsation to reduce infarct size pre-
PCI for acute myocardial infarction;
Principal Investigator: Marc Cohen, MD
Observational study of
alloimmunity in cardiac transplant from
the time of transplant to one-year posttransplant;
Principal Investigator:
David Baran, MD
Evaluation of the
safety and effectiveness the Duraheart Left
Ventricular Assist System in patients
awaiting heart transplantation; Principal
Investigator: Margarita Camacho, MD
Evaluation of
the HeartMate II Left Ventricular Assist
System as destination therapy versus the
HeartMate XVE System; Principal
Investigator: Margarita Camacho, MD
Invasive Monitoring Attenuation
Through Gene Expression Trial; Principal
Investigator: David Baran, MD
Phase II/III, double-blind,
randomized, controlled, multi-center
study to assess the safety and
cardiovascular effects of MYOCELL
implantation by a catheter delivery system
in congestive heart failure patients post
myocardial infarction(s); trial is
temporarily on hold waiting for a protocol
amendment from the FDA; Principal
Investigator: Mark J. Zucker, MD, JD
Human recombinant fibroblast
growth factor-1 (FGF-1141) for the
treatment of subjects with severe coronary
heart disease, a double-blind, placebocontrolled,
dose- varying study; Principal
Investigator: Mark J. Zucker, MD, JD
Randomized, partiallyblinded,
multi-center, active-controlled,
dose-ranging study assessing the safety,
efficacy and pharmacodynamics of REG1
Anticoagulation System compared to
unfractionated Harpain or low molecular
Heparin in subjects with acute coronary
syndrome; Principal Investigator: Marc
Cohen, MD
To learn more about the clinical trials
conducted at NBIMC please call the cardiac
research team at 973.926.8541.
[ top ]
|
